Search
Triclabendazole
go.drugbank.com/drugs/DB12245ApprovedInvestigationalTriclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often...
Categories: Cytochrome P-450 CYP1A1 Substrates, Cytochrome P-450 CYP1A2 InhibitorsSeviteronel
go.drugbank.com/drugs/DB12275InvestigationalSeviteronel has been used in trials studying the treatment of CRPC, Prostate Cancer, and Castration-resistant Prostate Cancer.
Categories: Cytochrome P-450 Enzyme InhibitorsDefactinib
go.drugbank.com/drugs/DB12282ApprovedInvestigationalDefactinib is a small molecule kinase inhibitor targeted against focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (Pyk2), the two members of the FAK family of nonreceptor tyrosine kinases. FAK is important for the integrin-...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersDoravirine
go.drugbank.com/drugs/DB12301ApprovedInvestigationalDoravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines. Doravirine is available by itself or as a combination product of doravirine (10...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesRucaparib
go.drugbank.com/drugs/DB12332ApprovedInvestigationalRucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of a...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 InhibitorsSeladelpar
go.drugbank.com/drugs/DB12390ApprovedInvestigationalSeladelpar is a peroxisome proliferator-activated receptor (PPAR)-delta (δ) agonist. Seladelpar is a single enantiomer of the R-configuration. On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment o...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesSagopilone
go.drugbank.com/drugs/DB12391InvestigationalSagopilone has been used in trials studying the treatment of Melanoma, Neoplasms, CNS Disease, Breast Cancer, and Breast Neoplasms, among others. It is a so-called fully synthetic epothilone and is the first such compound to be in clinic...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsSulforaphane
go.drugbank.com/drugs/DB12422InvestigationalSulforaphane is under investigation for the treatment of Autism Spectrum Disorder. It is a naturally occurring isothiocyanate found in high concentration in a variety of broccoli.
Categories: Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 Enzyme InhibitorsRimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigationalRimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commissio...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesKetanserin
go.drugbank.com/drugs/DB12465InvestigationalKetanserin has been investigated for the treatment of Septic Shock, Severe Sepsis, and Diabetic Foot Ulcer.
Mixtures: SUFREXAL P